An interventional study of Fibroscan in Tissue and Organ Harvesting, Liver Transplantation and Brain Death, sponsored by University Hospital, Limoges. Completed at 19 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-24.
Sponsored by University Hospital, Limoges · Not applicable, Interventional, and Diagnostic
According to the French Biomedicine Agency annual report on retrieval activities and transplants, 1,164 liver transplants were performed in 2011 and 1,161 in 2012. If the amount of brain death donors and retrieved liver grafts appears relatively stable, it remains clearly insufficient compared to the increasing number of patients on the waiting list for liver transplantation (2,462 in 2011). The median time on the waiting list before liver transplantation which was established from the cohort of patients registered between 2007 and 2011 (excluding patients registered for emergency transplantation and for living related-donor transplantation) increased significantly from 4.4 months between 2007 and 2009 to 6.6 months between 2010 and 2011. In order to compensate for the lack of liver grafts, donors acceptance criteria were broadened. For example, alternative transplantation lists were created with liver grafts coming from so-called "marginal" donors. However, despite these efforts, livers were retrieved on only two out of three brain death donors, i.e. in 1,572 and 1,589 organ donors in 2011 and 2012, respectively. This is unfortunately not enough to meet the increasing needs in liver grafts and a growing number of patients wait each year for transplant. Strategic lines of improvement were defined in order to meet the "2012-2016 transplant perspective" which targets 5,700 transplants carried out in 2015 (+5% every year, all transplants included, with 5,023 transplants in 2012).
According to the last consensus conference on liver transplantation of the HAS (French High Authority of Health) the assessment of the degree of macrovacuolar and microvacuolar steatosis determines the possibility to retrieve the graft or not. Liver steatosis consists in an accumulation of fatty droplets in hepatocytes. Its prevalence is high, ranging from 16% to 31% in the general population, and increases up to 46% in heavy drinkers and to 50-80% in the obese population. Steatosis results mostly from alcohol consumption and from metabolic syndrome (obesity, type 2 diabetes, hypertriglyceridemia) called non-alcoholic fatty liver disease (NAFLD), and is more rarely secondary to viral hepatitis or exposure to certain medications. NAFLD involves up to 30% of the population in Western countries and its prevalence is increasing. NAFLD may lead to asymptomatic steatosis, but also to steatohepatitis or advanced fibrosis including cirrhosis and its complications Accordingly, the improvement of liver grafts selection based on objective quantitative criteria which takes into account the degree of liver steatosis appears crucial to increase the number of hepatic transplants.
Medical procedure: Fibroscan® based on vibration control transient elastography (VCTETM) with evaluation of controlled attenuation parameter (CAP™) by ultrasounds (Echosens, Paris, France).
Exclusion Criteria:
All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
Procedure: Fibroscan
All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
Controlled Attenuation Parameter™ (CAP™) measurement
Evaluation of the diagnostic accuracy of the CAP™ measured with Fibroscan® to objectively reflect the degree of liver steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in donors with brain death (DBD).
Time frame: 1 Day
Liver Stiffness (LS) measurement
Evaluation of the diagnostic accuracy of LS measured with Fibroscan® to objectively reflect the degree of fibrosis and steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in DBD
Time frame: 1 Day
Controlled Attenuation Parameter™ (CAP™) measurement
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week after transplantation
Time frame: 1 week
Liver Stiffness (LS) measurement
Determination of the prognostic value of LS in terms of survival of liver grafts at one week after transplantation
Time frame: 1 week
Liver Stiffness (LS) measurement
Determination of the prognostic value of LS in terms of survival of liver grafts at one month after transplantation
Time frame: 1 month
Controlled Attenuation Parameter™ (CAP™) measurement
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one month after transplantation
Time frame: 1 month
Liver Stiffness (LS) measurement
Determination of the prognostic value of LS in terms of survival of liver grafts at one week, one month and one year after transplantation
Time frame: 1 year
Controlled Attenuation Parameter™ (CAP™) measurement
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week, one month and one year after transplantation
Time frame: 1 year
Fibrosis measurement
evaluate the diagnostic a accuracy of FibroTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS
Time frame: 1 Day
Steatosis measurement
evaluate the diagnostic a accuracy of SteatoTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS
Time frame: 1 Day
Fibrosis measurement
Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one month after transplantation
Time frame: 1 month
Steatosis measurement
Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one month after transplantation
Time frame: 1 month
Fibrosis measurement
Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one year after transplantation
Time frame: 1 year
Steatosis measurement
Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one year after transplantation
Time frame: 1 year
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Limoges